A cross-sectional study on vision-related quality of life in patients with ocular GvHD

Bone Marrow Transplant. 2015 Sep;50(9):1224-6. doi: 10.1038/bmt.2015.24. Epub 2015 Jun 8.


Ocular GvHD affects about 40-60% of patients receiving bone marrow transplantation. Ocular complaints worsen quality of life (QoL), which, besides survival time, is a primary end point in a patient's follow-up. The aim of our study was to assess the ocular surface status and vision-related QoL (VRQoL) and explore the potential determinants in VRQoL in patients with chronic GvHD with ocular involvement. In this cross-sectional study, we investigated 40 patients with ocular GvHD after allogeneic hematopoietic stem cell transplantation assessing ocular symptoms and signs, VRQoL and ophthalmologic parameters. The median age was 52.1 years; 32.5% were females. Most of them presented a multiple organ involvement. Ophthalmological parameter examinations were on average abnormal. Corneal staining was severe/very severe in 25%; conjunctival staining in 10% of subjects. The worse QoL scores were on 'general vision', 'ocular pain', 'vision-specific mental health' and 'vision-specific role difficulties'. Both symptoms and sign scores indicate poor VRQoL. A lower VRQoL was related to schooling level, job position, underlying disease and extracorporeal photopheresis. Corneal staining, Schirmer and tear film breakup time were negatively associated to visual function-related subscales. An accurate ophthalmological and VRQoL assessment should be mandatory for a long time to promptly recognize early signs of ocular suffering, and to prevent irreversible ocular complications.

Publication types

  • Clinical Trial

MeSH terms

  • Allografts
  • Cross-Sectional Studies
  • Female
  • Follow-Up Studies
  • Glaucoma* / epidemiology
  • Glaucoma* / etiology
  • Glaucoma* / pathology
  • Glaucoma* / physiopathology
  • Graft vs Host Disease* / epidemiology
  • Graft vs Host Disease* / etiology
  • Graft vs Host Disease* / pathology
  • Graft vs Host Disease* / physiopathology
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Male
  • Middle Aged
  • Quality of Life*